SCHEMBL20183650

SCHEMBL20183650

CCn1c(=O)cc(C(C)C)c2cc(C(=O)N(C)c3ccc(Cl)cc3)ccc21

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 3/20 0.40
HTT P42858 2/20 0.40
GLA P06280 1/20 0.40
KDM4E B2RXH2 2/20 0.39
TP53 P04637 4/20 0.39
POLB P06746 2/20 0.39
LMNA P02545 2/20 0.38
HSP90AA1 P07900 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RORC P51449 1/20 0.37
LIPE Q05469 1/20 0.36
HSD17B10 Q99714 2/20 0.36
ITK Q08881 2/20 0.36
INSR P06213 1/20 0.36
TXK P42681 1/20 0.36
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20183809 0.94 MAPT (0.40) ALDH1A1SMN1; SMN2MAPTHTTGLA
SCHEMBL20354318 0.91 KDM4E (0.42) SMN1; SMN2MAPTGLAKDM4ETP53
SCHEMBL20354281 0.88 KDM4E (0.38) ALDH1A1SMN1; SMN2MAPTHTTKDM4E
SCHEMBL20183791 0.88 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2MAPTKDM4ETP53
SCHEMBL20183774 0.87 RORC (0.36) ALDH1A1SMN1; SMN2MAPTKDM4ETP53
SCHEMBL20183854 0.87 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2MAPTHTTGLA
SCHEMBL20183714 0.87 TUBB4A (0.44) MAPTKDM4ETP53RORC
SCHEMBL20183788 0.87 LMNA (0.38) SMN1; SMN2MAPTKDM4ETP53LMNA
SCHEMBL20183857 0.86 RXFP1 (0.40) ALDH1A1SMN1; SMN2MAPTTP53POLB
SCHEMBL21474015 0.86 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2MAPTHTTGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10987349-B2 Antitumor agent and bromodomain inhibitor FUJIFILM CORPORATION (JP) 2021-04-27 US disclosed
US-10987349-B2 Antitumor agent and bromodomain inhibitor FUJIFILM CORPORATION (JP) 2021-04-27 US disclosed
EP-3563851-B1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORP (JP) 2021-04-21 EP disclosed
EP-3327004-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORP (JP) 2020-11-04 EP disclosed
US-10696637-B2 Nitrogen-containing heterocyclic compound FUJIFILM CORPORATION (JP) 2020-06-30 US disclosed
US-10696637-B2 Nitrogen-containing heterocyclic compound FUJIFILM CORPORATION (JP) 2020-06-30 US disclosed
US-10633343-B2 2020-04-28 US disclosed
US-10633343-B2 2020-04-28 US disclosed
EP-3563851-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM Corporation (JP) 2019-11-06 EP disclosed
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORPORATION (JP) 2019-10-17 US disclosed
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORPORATION (JP) 2019-10-17 US disclosed
US-20190077761-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORPORATION (JP) 2019-03-14 US disclosed
US-20190077761-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORPORATION (JP) 2019-03-14 US disclosed
WO-2018124180-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR 富士フイルム株式会社 2018-07-05 WO disclosed
EP-3327004-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Fujifilm Corporation (JP) 2018-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10987349-B2 Antitumor agent and bromodomain inhibitor BRD4, BRD1, BRD3 ALDH1A1 3243/4885SMN1; SMN2 4557/4885MAPT 3928/4885
US-10696637-B2 Nitrogen-containing heterocyclic compound CXCL10, CCL5, CXCR3 ALDH1A1 3095/4885SMN1; SMN2 3085/4885MAPT 4325/4885
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR BRD4, BRD1, BRD3 ALDH1A1 3243/4885SMN1; SMN2 4557/4885MAPT 3928/4885
US-20190077761-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND CXCL10, CCL5, CXCR3 ALDH1A1 3095/4885SMN1; SMN2 3085/4885MAPT 4325/4885
US-10633343-B2 CXCL10, CCL5, CXCR3 ALDH1A1 2674/4885SMN1; SMN2 3653/4885MAPT 4406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.